REDUCE-IT Study On-Track for Reporting Top-Line
Results by the End of Q3 2018
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular health, today announced
financial results for the three months ended March 31, 2018, and
provided an update on company operations.
Key Amarin achievements through March 31, 2018
include:
- R&D progress: The REDUCE-IT cardiovascular outcomes study,
designed to provide data to support a significantly expanded market
opportunity for Vascepa® (icosapent ethyl), is estimated to have
reached the 100% mark for onset of the 1,612 target primary major
adverse cardiovascular events (MACE) specified in the study design.
Amarin anticipates that MACE from the study will be adjudicated
through Q2 2018, consistent with the company's objective of
reporting top-line results from this important study before the end
of Q3 2018.
- U.S. revenue growth: Recognized $43.8 million in net product
revenue from Vascepa sales in Q1 2018 compared to $34.3 million in
Q1 2017, an increase of 27%.
- U.S. prescription growth: Increased normalized prescriptions
for Vascepa by 25% and 27% compared to Q1 2017 based on data from
Symphony Health Solutions and IQVIA, respectively.
- International development: Announced the first international
approval for Vascepa with the regulatory approval of Vascepa in
Lebanon. The clinical trial of Vascepa for approval in China is in
process.
- Cash balance: As of March 31, 2018, Amarin had a cash balance
of $129.0 million, which includes approximately $70.0 million in
net cash proceeds from the equity offering announced in February
2018, compared to $73.6 million at December 31, 2017.
“There is tremendous energy and excitement
within Amarin currently as we approach the results of the REDUCE-IT
study and prepare for targeted future growth,” stated John F.
Thero, president and chief executive officer. “The unmet medical
need remains large for cost-effective therapies that lower
cardiovascular risk beyond the risk reduction achieved with
standard of care statin therapy alone. We are pleased that
increasing numbers of physicians are prescribing Vascepa to help
their patients and we are confident that the results from the
REDUCE-IT study will lead to better informed decisions regarding
patient care.”
REDUCE-IT Cardiovascular Outcomes
Study
REDUCE-IT is designed to determine if
intervention with 4 grams/day of prescription pure EPA Vascepa will
lower rates of major adverse cardiovascular events in
statin-treated patients with persistent hypertriglyceridemia and
other cardiovascular risk factors. Motivated by the vision of
Amarin and its scientific collaborators in identifying a large
unmet medical need in this important patient population, and
facilitated by the differentiation of Vascepa from earlier
generation triglyceride-lowering therapies, this is the first ever
prospective study of this population with any therapy.
The primary endpoint of this global,
double-blind study is the time to the first occurrence of a
composite of primary major adverse cardiovascular events
(MACE). Results will be compared between the Vascepa and
placebo groups. The study was designed to accumulate 1,612 MACE at
which level the study was robustly designed to have 90% power to
detect a 15% relative risk reduction in MACE between the Vascepa
and placebo arms of the study. The study is being conducted under a
Special Protocol Assessment (SPA) agreement with the FDA.
As previously reported, Amarin estimates that
the onset of approximately 1,612 MACE has occurred. In March 2018,
patients in the study began to complete their final clinical site
visits, a key step towards study completion.
Amarin is intentionally blinded to the results
of the study and will remain blinded to such results until after
the study is completed and the database is locked. Final patient
visits will be followed by completing data entry for the more than
35,000 patient years of study in REDUCE-IT, and typical database
quality control measures, known as cleaning. In parallel,
adjudication will be completed for all MACE which occurred during
the study, including adjudication for certain events which, per
protocol, cannot be finally adjudicated until patients complete
their final site visit and results are available from certain
non-invasive diagnostic testing conducted during such site visits.
These steps will be followed by the database lock and final
efficacy and safety analyses, including analysis of the trial's
primary endpoint of first MACE events in the study, and the
analyses of more than thirty pre-defined secondary and tertiary
endpoints. Winding down a study of this magnitude to
completion typically takes many months. The company believes that
it is on track to achieve its objective of reporting top-line
results from this important study before the end of Q3 2018.
Financial Update
Net product revenue for the three months ended
March 31, 2018 and 2017 was $43.8 million and $34.3 million,
respectively. The increase in net product revenue was primarily
attributable to increases in new and recurring prescriptions of
Vascepa.
During the first quarter, based on data from
Symphony Health Solutions and IQVIA, Amarin experienced continued
prescription growth and increase in Vascepa market share,
particularly among detailed physicians. These sources reported
estimated normalized total Vascepa prescriptions of approximately
381,000 and 392,000, respectively, for the three months ended March
31, 2018, representing growth of approximately 25% and 27%,
respectively, over levels reported for the first three months of
the prior year.
The company recognized licensing revenue of $0.1
million and $0.3 million in the three months ended March 31, 2018
and 2017, respectively, related to agreements for the
commercialization of Vascepa outside the United States.
Cost of goods sold for the three months ended
March 31, 2018 and 2017 was $10.6 million and $8.2 million,
respectively. Gross margin on net product revenue was 76% for
each of the three months ended March 31, 2018 and 2017.
Selling, general and administrative expenses in
the three months ended March 31, 2018 and 2017 were $43.4 million
and $34.2 million, respectively. This increase is due primarily to
increased promotional activities, including commercial spend for
anticipated expansion following successful REDUCE-IT results, and
increased co-promotion fees, including an accrual for co-promotion
tail payments as well as an increase in co-promotion fees
calculated on increased gross margin resulting from higher net
product revenue. The tail co-promotion fees, which are calculated
as a percentage of the 2018 co-promotion fee, are payable in 2019
through 2021. Such tail co-promotion fees will be accrued
throughout 2018.
Research and development expenses in the three
months ended March 31, 2018 and 2017 were $11.8 million and $10.8
million, respectively. This increase in expense was primarily
driven by the timing of REDUCE-IT and related costs.
Under U.S. GAAP, Amarin reported a net loss of $24.1 million in the
first quarter of 2018, or basic and diluted loss per share of
$0.08. This net loss included $3.8 million in non-cash stock-based
compensation expense. Amarin reported a net loss of $20.9 million
in the first quarter of 2017, or basic and diluted loss per share
of $0.08. This net loss included $3.4 million in non-cash
stock-based compensation expense.
Excluding non-cash gains or losses for
stock-based compensation, non-GAAP adjusted net loss was $20.3
million for the first quarter of 2018, or non-GAAP adjusted basic
and diluted loss per share of $0.07, compared to non-GAAP adjusted
net loss of $17.6 million for the first quarter of 2017, or
non-GAAP adjusted basic and diluted loss per share of $0.07.
Amarin reported cash and cash equivalents of
$129.0 million as of March 31, 2018. Excluding proceeds from the
equity financing completed in the first quarter and excluding other
financing-related amounts (interest and royalty) and without the
company’s high level of research and development payments, most of
which relates to advancing the REDUCE-IT study to completion this
year, net cash outflow in the quarter ended March 31, 2018 was
approximately $0.1 million. Cash outflows relating to research and
development in Q1 2018 totaled approximately $11.3 million and cash
paid for interest and royalties, in aggregate, was approximately
$5.9 million.
As of March 31, 2018, the company had $39.2
million in net accounts receivable ($57.6 million in gross accounts
receivable before allowances and reserves) and $35.1 million in
inventory.
As of March 31, 2018, Amarin had approximately
293.6 million American Depository Shares (ADSs) and ordinary shares
outstanding, 32.8 million common share equivalents of Series A
Convertible Preferred Shares outstanding and approximately 25.7
million equivalent shares underlying stock options at a
weighted-average exercise price of $3.35, as well as 12.4 million
equivalent shares underlying restricted or deferred stock
units.
Amarin’s partner in the Middle East and North
Africa, or MENA region, in the first quarter of 2018 obtained
approval for Vascepa in Lebanon. Amarin anticipates additional
approvals in the MENA region, including potential additional
approvals in 2018. Amarin’s partner for China, Eddingpharm, is
progressing in its clinical study of Vascepa in China. This
study, which recently commenced, potentially positions Vascepa to
be the first prescription grade EPA product to receive drug
approval in China.
Conference call and webcast
information
Amarin will host a conference call
at 7:30 a.m. ET today, May 2, 2018. The call
will be webcast live with slides and accessible through the
investor relations section of the company’s website at
www.amarincorp.com. The call can also be heard via telephone by
dialing 877-407-8033. A replay of the call will be made available
for a period of two weeks following the conference call. To hear a
replay of the call, dial 877-481-4010 (inside the United States) or
919-882-2331 (outside the United States). A replay of the call will
also be available through the company's website shortly after the
call. For both dial-in numbers please use conference ID 27922.
Use of non-GAAP adjusted financial
information
Included in this press release are non-GAAP
adjusted financial information as defined by U.S. Securities and
Exchange Commission Regulation G. The GAAP financial measure most
directly comparable to each non-GAAP adjusted financial measure
used or discussed, and a reconciliation of the differences between
each non-GAAP adjusted financial measure and the comparable GAAP
financial measure, is included in this press release after the
condensed consolidated financial statements.
Non-GAAP adjusted net loss was derived by taking
GAAP net loss and adjusting it for non-cash stock-based
compensation expense. Management uses these non-GAAP adjusted
financial measures for internal reporting and forecasting purposes,
when publicly providing its business outlook, to evaluate the
company’s performance and to evaluate and compensate the company’s
executives. The company has provided these non-GAAP financial
measures in addition to GAAP financial results because it believes
that these non-GAAP adjusted financial measures provide investors
with a better understanding of the company’s historical results
from its core business operations.
While management believes that these non-GAAP
adjusted financial measures provide useful supplemental information
to investors regarding the underlying performance of the company’s
business operations, investors are reminded to consider these
non-GAAP measures in addition to, and not as a substitute for,
financial performance measures prepared in accordance with GAAP.
Non-GAAP measures have limitations in that they do not reflect all
of the amounts associated with the company’s results of operations
as determined in accordance with GAAP. In addition, it should be
noted that these non-GAAP financial measures may be different from
non-GAAP measures used by other companies, and management may
utilize other measures to illustrate performance in the future.
About Amarin
Amarin Corporation plc is a biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular health. Amarin's
product development program leverages its extensive experience in
lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa® (icosapent ethyl),
Amarin's first FDA-approved product, is a highly-pure, omega-3
fatty acid product available by prescription. For more
information about Vascepa visit www.vascepa.com. For more
information about Amarin visit www.amarincorp.com.
About REDUCE-IT
Amarin's clinical development program for
Vascepa includes a trial known as the REDUCE-IT cardiovascular
outcomes study, an 8,175-patient study commenced in 2011. REDUCE-IT
is the first multinational cardiovascular outcomes study evaluating
the effect of prescription pure EPA therapy, or any
triglyceride-lowering therapy, as an add-on to statins in patients
with high cardiovascular risk who, despite stable statin therapy,
have elevated triglyceride levels (150-499 mg/dL). A large portion
of the male and female patients enrolled in this outcomes study are
anticipated to also be diagnosed with type 2 diabetes. As reported
previously, Amarin expects to announce top-line results of this
important study before the end of Q3 2018. The REDUCE-IT
trial is being conducted under a Special Protocol Assessment
agreement with the U.S. Food and Drug Administration.
Additional information on clinical studies of
Vascepa can be found at www.clinicaltrials.gov.
About VASCEPA® (icosapent ethyl)
capsules
Vascepa® (icosapent ethyl) capsules are a
single-molecule prescription product consisting of the omega-3 acid
commonly known as EPA in ethyl-ester form. Vascepa is not fish oil,
but is derived from fish through a stringent and complex
FDA-regulated manufacturing process designed to effectively
eliminate impurities and isolate and protect the single molecule
active ingredient. Vascepa, known in scientific literature as
AMR101, has been designated a new chemical entity by the FDA.
Amarin has been issued multiple patents internationally based on
the unique clinical profile of Vascepa, including the drug’s
ability to lower triglyceride levels in relevant patient
populations without raising LDL-cholesterol levels.
FDA-approved indication and usage
- Vascepa (icosapent ethyl) is
indicated as an adjunct to diet to reduce triglyceride (TG) levels
in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia.
- The effect of Vascepa on the risk
for pancreatitis and cardiovascular mortality and morbidity in
patients with severe hypertriglyceridemia has not been
determined.
Important safety information for Vascepa
- Vascepa is contraindicated in
patients with known hypersensitivity (e.g., anaphylactic reaction)
to Vascepa or any of its components.
- Use with caution in patients with
known hypersensitivity to fish and/or shellfish.
- The most common reported adverse
reaction (incidence > 2% and greater than placebo) was
arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no
reported adverse reaction > 3% and greater than placebo.
- Patients receiving treatment with
Vascepa and other drugs affecting coagulation (e.g., anti-platelet
agents) should be monitored periodically.
- In patients with hepatic
impairment, monitor ALT and AST levels periodically during
therapy.
- Patients should be advised to
swallow Vascepa capsules whole; not to break open, crush, dissolve,
or chew Vascepa.
- Adverse events and product
complaints may be reported by calling 1-855-VASCEPA or the FDA at
1-800-FDA-1088.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE
FOUND AT WWW.VASCEPA.COM.
Vascepa has been approved for use by the United
States Food and Drug Administration (FDA) as an adjunct to diet to
reduce triglyceride levels in adult patients with severe (≥500
mg/dL) hypertriglyceridemia. Nothing in this press release should
be construed as promoting the use of Vascepa in any indication that
has not been approved by the FDA.
About cardiovascular
disease
Worldwide, cardiovascular disease (CVD) remains
the #1 killer of men and women. In the United States, CVD leads to
one in every three deaths – one death approximately every 38
seconds – with annual treatment cost in excess of $500 billion.1,
2
Beyond the cardiovascular risk associated with
LDL-C, genetic, epidemiologic, clinical and real-world data suggest
that patients with elevated triglycerides (TG) (fats in the blood),
and TG-rich lipoproteins, are at increased risk for cardiovascular
disease. 3, 4, 5, 6
Leading clinical investigations seeking to
address cardiovascular risk reduction beyond lowering LDL-C focus
on interrupting the atherosclerotic process (e.g., plaque formation
and instability) by beneficially affecting other lipid, lipoprotein
and inflammation biomarkers and cellular functions thought to be
related to atherosclerosis and cardiovascular events.
Forward-looking statements
This press release contains forward-looking
statements, including expectations regarding adjudication of MACE
events, results and related timing and announcements with respect
to Amarin's REDUCE-IT cardiovascular outcomes study; expectations
related to the final outcomes of the REDUCE-IT study and the
anticipated successful completion of the REDUCE-IT study; and
statements regarding the potential and therapeutic benefits of
Vascepa. These forward-looking statements are not promises or
guarantees and involve substantial risks and uncertainties. In
particular, as disclosed in filings with the U.S. Securities and
Exchange Commission, Amarin's ability to effectively develop and
commercialize Vascepa will depend in part on its ability to
continue to effectively finance its business, efforts of third
parties, its ability to create market demand for Vascepa through
education, marketing and sales activities, to achieve increased
market acceptance of Vascepa, to receive adequate levels of
reimbursement from third-party payers, to develop and maintain a
consistent source of commercial supply at a competitive price, to
comply with legal and regulatory requirements in connection with
the sale and promotion of Vascepa and to maintain patent protection
for Vascepa. Among the factors that could cause actual results to
differ materially from those described or projected herein include
the following: uncertainties associated generally with research and
development, clinical trials and related regulatory approvals; the
risk that historical REDUCE-IT event rates may not be predictive of
future results and related cost may increase beyond expectations;
the risk that regulatory reviews may impact the current design of
the REDUCE-IT study or cause a change in strategic direction with
respect to continuation of the study; the risk that future legal
determinations and interactions with regulatory authorities may
impact Vascepa marketing and sales rights and efforts; the risk
that Vascepa may not show clinically meaningful effects in
REDUCE-IT or support regulatory approvals for cardiovascular risk
reduction; and the risk that patents may not be upheld in
anticipated patent litigation. A further list and description
of these risks, uncertainties and other risks associated with an
investment in Amarin can be found in Amarin’s filings with the U.S.
Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. Amarin undertakes no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise.
Availability of other information about
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (www.amarincorp.com), the investor relations website
(investor.amarincorp.com), including but not limited to investor
presentations and investor FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and
webcasts. The information that Amarin posts on these channels
and websites could be deemed to be material information. As a
result, Amarin encourages investors, the media, and others
interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time
to time on Amarin’s investor relations website and may include
social media channels. The contents of Amarin’s website or
these channels, or any other website that may be accessed from its
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
References
1 American Heart Association. 2018. Disease and
Stroke Statistics-2018 Update.
2 American Heart Association. 2017.
Cardiovascular disease: A costly burden for America projections
through 2035.
3 Budoff M. Triglycerides and triglyceride-rich lipoproteins in
the causal pathway of cardiovascular disease. Am J Cardiol.
2016;118:138-145.
4 Toth PP, Granowitz C, Hull M, et al. High triglycerides
increase cardiovascular events, medical costs, and resource
utilization in a real-world analysis of statin-treated patients
with high cardiovascular risk and well-controlled low-density
lipoprotein cholesterol [abstract]. Circulation. 2017;136(suppl
1):A15187.
5 Nordestgaard BG. Triglyceride-rich lipoproteins and
atherosclerotic cardiovascular disease - New insights from
epidemiology, genetics, and biology. Circ Res.
2016;118:547-563.
6 Nordestgaard BG, Varbo A. Triglycerides and cardiovascular
disease. Lancet. 2014; 384: 626–635.
Amarin contact information
Investor Relations:Elisabeth Schwartz Investor
Relations and Corporate Communications Amarin Corporation plc
In U.S.: +1 (908) 719-1315 investor.relations@amarincorp.com
Lee M. Stern Trout Group In U.S.: +1 (646)
378-2992lstern@troutgroup.com Media Inquiries: Kristie Kuhl
Finn Partners In U.S.: +1 (212) 583-2791
Kristie.kuhl@finnpartners.com
|
|
|
|
CONSOLIDATED BALANCE SHEET DATA |
|
(U.S. GAAP) |
|
Unaudited |
|
|
|
|
|
|
|
|
|
March 31, 2018 |
|
December 31, 2017 |
|
|
|
(in thousands) |
|
ASSETS |
|
|
|
|
|
Current
Assets: |
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
129,049 |
|
|
$ |
73,637 |
|
|
Restricted cash |
|
|
600 |
|
|
|
600 |
|
|
Accounts
receivable, net |
|
|
39,180 |
|
|
|
45,318 |
|
|
Inventory, net |
|
|
35,104 |
|
|
|
30,260 |
|
|
Prepaid
and other current assets |
|
|
3,618 |
|
|
|
3,455 |
|
|
Total current assets |
|
|
207,551 |
|
|
|
153,270 |
|
|
|
|
|
|
|
|
Property,
plant and equipment, net |
|
|
20 |
|
|
|
28 |
|
|
Other
long-term assets |
|
|
174 |
|
|
|
174 |
|
|
Intangible asset, net |
|
|
7,964 |
|
|
|
8,126 |
|
|
TOTAL ASSETS |
|
$ |
215,709 |
|
|
$ |
161,598 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
Current
Liabilities: |
|
|
|
|
|
Accounts
payable |
|
$ |
31,877 |
|
|
$ |
25,155 |
|
|
Accrued
expenses and other current liabilities |
|
|
61,311 |
|
|
|
58,902 |
|
|
Current
portion of exchangeable senior notes, net of discount |
|
|
219 |
|
|
|
481 |
|
|
Current
portion of long-term debt from royalty-bearing instrument |
|
|
24,370 |
|
|
|
22,348 |
|
|
Deferred
revenue, current |
|
|
1,453 |
|
|
|
1,644 |
|
|
Total current liabilities |
|
|
119,230 |
|
|
|
108,530 |
|
|
|
|
|
|
|
|
Long-Term
Liabilities: |
|
|
|
|
|
Exchangeable senior notes, net of discount |
|
|
29,047 |
|
|
|
28,992 |
|
|
Long-term
debt from royalty-bearing instrument |
|
|
65,480 |
|
|
|
70,834 |
|
|
Deferred
revenue, long-term |
|
|
17,459 |
|
|
|
17,192 |
|
|
Other
long-term liabilities |
|
|
1,150 |
|
|
|
1,150 |
|
|
Total liabilities |
|
|
232,366 |
|
|
|
226,698 |
|
|
|
|
|
|
|
|
Stockholders’ Deficit: |
|
|
|
|
|
Preferred
Stock |
|
|
24,364 |
|
|
|
24,364 |
|
|
Common
stock |
|
|
225,246 |
|
|
|
208,768 |
|
|
Additional paid-in capital |
|
|
1,036,697 |
|
|
|
977,866 |
|
|
Treasury
stock |
|
|
(6,782 |
) |
|
|
(4,229 |
) |
|
Accumulated deficit |
|
|
(1,296,182 |
) |
|
|
(1,271,869 |
) |
|
Total stockholders’ deficit |
|
|
(16,657 |
) |
|
|
(65,100 |
) |
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
$ |
215,709 |
|
|
$ |
161,598 |
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS
DATA |
|
(U.S. GAAP) |
|
Unaudited |
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
|
(in thousands, except per share
amounts) |
|
|
|
|
2018 |
|
|
|
2017 |
|
|
Product revenue, net |
$ |
43,777 |
|
|
$ |
34,344 |
|
|
Licensing revenue |
|
142 |
|
|
|
293 |
|
|
Total
revenue, net |
|
43,919 |
|
|
|
34,637 |
|
|
Less: Cost of goods sold |
|
10,648 |
|
|
|
8,198 |
|
|
Gross margin |
|
33,271 |
|
|
|
26,439 |
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
Selling,
general and administrative (1) |
|
43,407 |
|
|
|
34,171 |
|
|
Research
and development (1) |
|
11,762 |
|
|
|
10,823 |
|
|
Total
operating expenses |
|
55,169 |
|
|
|
44,994 |
|
|
|
|
|
|
|
|
Operating loss |
|
(21,898 |
) |
|
|
(18,555 |
) |
|
|
|
|
|
|
|
Interest expense, net |
|
(2,252 |
) |
|
|
(2,381 |
) |
|
Other income (expense), net |
|
55 |
|
|
|
(5 |
) |
|
Loss from operations before taxes |
|
(24,095 |
) |
|
|
(20,941 |
) |
|
(Provision for) benefit from income taxes |
|
— |
|
|
|
— |
|
|
Net loss |
$ |
(24,095 |
) |
|
$ |
(20,941 |
) |
|
|
|
|
|
|
|
Loss per share: |
|
|
|
|
Basic |
$ |
(0.08 |
) |
|
$ |
(0.08 |
) |
|
Diluted |
$ |
(0.08 |
) |
|
$ |
(0.08 |
) |
|
|
|
|
|
|
|
Weighted average shares outstanding: |
|
|
|
|
Basic |
|
285,207 |
|
|
|
270,163 |
|
|
Diluted |
|
285,207 |
|
|
|
270,163 |
|
|
|
|
|
|
|
|
(1 |
) |
Excluding non-cash stock-based compensation, selling, general
and administrative expenses were $40,205 and $31,343 for the three
months ended March 31, 2018 and 2017, respectively, and research
and development expenses were $11,202 and $10,300, respectively,
for the same periods. Excluding non-cash stock-based compensation
as well as co-promotion fees paid to the company's U.S.
co-promotion partner, selling, general and administrative expenses
were $31,134 and $26,111 for the three months ended March 31, 2018
and 2017, respectively. |
|
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF NON-GAAP NET
LOSS |
|
|
Unaudited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
|
|
|
(in thousands, except per share
amounts) |
|
|
|
|
|
|
2018 |
|
|
|
|
2017 |
|
|
|
Net loss for EPS1 - GAAP |
|
$ |
(24,095 |
) |
|
|
$ |
(20,941 |
) |
|
|
|
Non-cash
stock-based compensation expense |
|
|
3,762 |
|
|
|
|
3,351 |
|
|
|
Adjusted net loss for EPS1 - non-GAAP |
|
$ |
(20,333 |
) |
|
|
$ |
(17,590 |
) |
|
|
|
|
|
|
|
|
|
|
|
1basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share: |
|
|
|
|
|
|
|
Basic and diluted - non-GAAP |
|
$ |
(0.07 |
) |
|
|
$ |
(0.07 |
) |
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares: |
|
|
|
|
|
|
|
Basic and diluted |
|
|
285,207 |
|
|
|
|
270,163 |
|
|
|
|
|
|
|
|
|
|
|
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024